prednisolone has been researched along with MS (Multiple Sclerosis) in 118 studies
Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.
prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Twenty-six acute exacerbations in 26 patients with early definite multiple sclerosis (MS) were treated with oral cyclosporin-A (CyA) or oral prednisolone in a double-blind, controlled and randomized trial." | 9.07 | Treatment of acute exacerbations in early multiple sclerosis: cyclosporin A or prednisolone? ( Eskola, J; Halonen, P; Panelius, M; Ruutiainen, J; Salmi, A; Salonen, R, 1991) |
| "The dynamics of the immunological parameters was studied in 17 patients with multiple sclerosis (MS) who received prednisolone therapy in combination with plasmacytapheresis." | 7.67 | [The dynamics of immunological indicators in the treatment of patients with multiple sclerosis with prednisolone combined with plasmapheresis]. ( Gannushkina, IV; Kir'iakov, VA; Neretin, VIa; Sapfirova, VA; Zhirnova, IG, 1988) |
| "A retrospective analysis of 350 treatment courses using high dose pulsed intravenous methylprednisolone for relapses of multiple sclerosis revealed a low number of adverse effects." | 7.67 | Methylprednisolone therapy in multiple sclerosis: a profile of adverse effects. ( Lyons, PR; Newman, PK; Saunders, M, 1988) |
| "Azathioprine treatment did not significantly lower quantitative synthesis." | 5.28 | Intrathecal immunoglobulin synthesis in multiple sclerosis: effect of corticosteroids and azathioprine. ( Aguayo, F; Alvarez, C; Berciano, J; Garrido, JC; Miró, J; Pascual, J; Polo, JM, 1992) |
| "Twenty-six acute exacerbations in 26 patients with early definite multiple sclerosis (MS) were treated with oral cyclosporin-A (CyA) or oral prednisolone in a double-blind, controlled and randomized trial." | 5.07 | Treatment of acute exacerbations in early multiple sclerosis: cyclosporin A or prednisolone? ( Eskola, J; Halonen, P; Panelius, M; Ruutiainen, J; Salmi, A; Salonen, R, 1991) |
| "30 multiple sclerosis patients in a double-blind, controlled trial were given immunosuppressive treatment consisting of antilymphocyte globulin, prednisolone, and azathioprine, or placebo." | 5.05 | Double-blind, controlled trial of immunosuppression in treatment of multiple sclerosis. ( Healy, MJ; Knight, SC; Mertin, J; Rudge, P; Thompson, EJ, 1980) |
| "In a double-blind controlled trial 43 patients with relapsing-remitting multiple sclerosis were treated either with anti-lymphocyte globulin, prednisolone, and azathioprine, or with placebo preparations." | 5.05 | Double-blind controlled trial of immunosuppression in the treatment of multiple sclerosis: final report. ( Batchelor, JR; Compston, A; Denman, M; Halliday, AM; Healey, MJ; Knight, SC; Kremer, M; Medawar, PB; Mertin, J; Rudge, P; Thompson, EJ, 1982) |
| "Serum levels of IL-6, sIL-6Ralpha, sgp130 and bone turnover markers were assessed before and each day during treatment in 24 multiple sclerosis (MS) patients undergoing high-dose (prednisolone, 15 mg/kg per day), short-term (3 to 5 days) intravenous GC therapy for relapse at the Regional Multiple Sclerosis Centre." | 3.73 | High-dose glucocorticoids increase serum levels of soluble IL-6 receptor alpha and its ratio to soluble gp130: an additional mechanism for early increased bone resorption. ( Angeli, A; Bertolotto, A; Capobianco, M; Dovio, A; Perazzolo, L; Saba, L; Termine, A, 2006) |
| "The authors examined 56 patients suffering of multiple sclerosis who were treated with prednisolone and Proper-Myl." | 3.68 | [Changes in the immunological reactivity of patients with disseminated sclerosis treated by prednisolone and the preparation Proper-Myl]. ( Iarosh, AA; Macheret, EL; Zapadniuk, BV, 1990) |
| "Changes in the apparently unaffected cerebral white matter of multiple sclerosis (MS) patients were studied during acute attacks as well as during high-dose prednisolone therapy." | 3.67 | Changes within the "normal" cerebral white matter of multiple sclerosis patients during acute attacks and during high-dose cortisone therapy assessed by means of quantitative MRI. ( Brainin, M; Deecke, L; Lang, S; Maida, E; Neuhold, A; Reisner, T, 1989) |
| "The dynamics of the immunological parameters was studied in 17 patients with multiple sclerosis (MS) who received prednisolone therapy in combination with plasmacytapheresis." | 3.67 | [The dynamics of immunological indicators in the treatment of patients with multiple sclerosis with prednisolone combined with plasmapheresis]. ( Gannushkina, IV; Kir'iakov, VA; Neretin, VIa; Sapfirova, VA; Zhirnova, IG, 1988) |
| "A retrospective analysis of 350 treatment courses using high dose pulsed intravenous methylprednisolone for relapses of multiple sclerosis revealed a low number of adverse effects." | 3.67 | Methylprednisolone therapy in multiple sclerosis: a profile of adverse effects. ( Lyons, PR; Newman, PK; Saunders, M, 1988) |
| "The effectiveness of high-dose intravenous corticosteroid therapy for acute bouts of multiple sclerosis (MS) was evaluated in comparison with the conventional oral prednisolone therapy." | 3.67 | High-dose intravenous corticosteroids in the treatment of multiple sclerosis. ( Hamaguchi, K; Ohno, R; Sowa, K; Tanaka, H; Watanabe, Y, 1987) |
| "Prednisolone was prescribed per os in a dose of 1." | 2.66 | [Corticosteroid therapy of multiple sclerosis with attention to biorhythms]. ( Bagdasarova, IA; Lobzin, VS, 1986) |
| "Short term high dose corticosteroid treatment improves symptoms and short term disability after an acute exacerbation of multiple sclerosis (MS) but it is unknown whether its long-term use can reduce the accumulation of disability." | 2.44 | Corticosteroids for the long-term treatment in multiple sclerosis. ( Beretta, S; Brusaferri, F; Ciccone, A; Galea, I; Protti, A; Spreafico, C, 2008) |
| "Development of autoimmune hepatitis (AIH) has been sporadically reported in patients with multiple sclerosis (MS) either concurrently or after treatment with immunomodulatory drugs, including interferon-beta (IFN-β) and steroids." | 1.51 | Autoimmune hepatitis in patients with multiple sclerosis: The role of immunomodulatory treatment. ( Arvaniti, P; Dalekos, GN; Gyftaki, S; Hadjigeorgiou, G; Koukoulis, GK; Rigopoulou, EI; Tsimourtou, V, 2019) |
| "We speculate that stabbing headache may develop as a result of neuroinflammation and, at least in some cases, may be an epiphenomenon of focal demyelinating lesions of the upper or lower brain stem." | 1.38 | Stabbing headache in patients with autoimmune disorders. ( Battaglia, G; Malaguarnera, M; Nicoletti, G; Rampello, L, 2012) |
| "The head tremor was the so-called "yes-yes" type which shakes back and forth." | 1.37 | [Case of multiple sclerosis with "yes-yes" type head tremor]. ( Itoyama, Y; Izumi, R; Nagata, M; Nakashima, I; Nishiyama, S; Omata, K; Suzuki, N, 2011) |
| " In this cross-sectional study we show that MS patients treated with IFN-β alone or in combination with low-dose prednisolone displayed increased proportion of all NK cell subsets in the active phase of the cell cycle (Ki-67+)." | 1.37 | Increase of Ki-67+ natural killer cells in multiple sclerosis patients treated with interferon-β and interferon-β combined with low-dose oral steroids. ( Aranami, T; Chihara, N; Gran, B; Lin, Y; Ogawa, M; Okamoto, T; Sanvito, L; Tomita, A; Yamamura, T, 2011) |
| "Multiple sclerosis is associated with iridocyclitis, intermediate uveitis, retinal periphlebitis, and optic neuritis." | 1.37 | Bilateral rubeosis iridis and rubeotic glaucoma due to peripheral occlusive vasculitis associated with multiple sclerosis. ( Deane, J; Dharmasena, A; Turner, SJ, 2011) |
| "Both ulcerative colitis and multiple sclerosis were eventually well controlled using this regimen." | 1.34 | Development of ulcerative colitis in a patient with multiple sclerosis following treatment with interferon beta 1a. ( Baumgart, DC; Paul, F; Rudolph, B; Schott, E; Wiedenmann, B; Wuerfel, JT; Zipp, F, 2007) |
| "We reported a case of hypogeusia in a 9-year-old girl with multiple sclerosis (MS)." | 1.34 | [Hypogeusia in a 9-year-old girl with multiple sclerosis]. ( Higuchi, K; Ihara, T; Takahashi, J; Yonekawa, T, 2007) |
| "The association between cluster headache and MS has been rarely described before." | 1.34 | Cluster headache attacks and multiple sclerosis. ( Ferrero, M; Gentile, S; Pinessi, L; Rainero, I; Vaula, G, 2007) |
| " The dosage of prednisolone was tapered, without a relapse, and then the corticosteroid therapy was stopped." | 1.33 | Nephrotic syndrome associated with interferon-beta-1b therapy for multiple sclerosis. ( Fujita, T; Kumasaka, R; Murakami, R; Nakamura, M; Nakamura, N; Okumura, K; Osawa, H; Shimada, M; Shirato, K; Yamabe, H, 2006) |
| "As a strategy to treat patients with multiple sclerosis in their third trimester of pregnancy, it is appropriate to evaluate disease activity using MRI and to start steroid pulse therapy after delivery." | 1.30 | [A case of multiple sclerosis with relapses during the third trimester of pregnancy]. ( Hirade, S; Inoue, H; Nagasawa, H; Takashima, S, 1997) |
| "Azathioprine treatment did not significantly lower quantitative synthesis." | 1.28 | Intrathecal immunoglobulin synthesis in multiple sclerosis: effect of corticosteroids and azathioprine. ( Aguayo, F; Alvarez, C; Berciano, J; Garrido, JC; Miró, J; Pascual, J; Polo, JM, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 46 (38.98) | 18.7374 |
| 1990's | 28 (23.73) | 18.2507 |
| 2000's | 24 (20.34) | 29.6817 |
| 2010's | 17 (14.41) | 24.3611 |
| 2020's | 3 (2.54) | 2.80 |
| Authors | Studies |
|---|---|
| Hu, H | 1 |
| Reddell, S | 1 |
| Riminton, S | 1 |
| Chan, C | 1 |
| Urriola, N | 1 |
| Rahmati, M | 1 |
| Ghannadian, SM | 1 |
| Kasiri, N | 1 |
| Ahmadi, L | 1 |
| Motedayyen, H | 1 |
| Shaygannejad, V | 1 |
| Pourazar, A | 1 |
| Alsahebfosoul, F | 1 |
| Ganjalikhani Hakemi, M | 1 |
| Eskandari, N | 1 |
| Naser Moghadasi, A | 1 |
| Shabany, M | 1 |
| Heidari, H | 1 |
| Eskandarieh, S | 1 |
| Yuen, HLA | 1 |
| Brown, S | 1 |
| Chan, N | 1 |
| Grigoriadis, G | 1 |
| Ngu, S | 1 |
| Shaffrali, F | 1 |
| Madeley, J | 1 |
| Hodges, G | 1 |
| Birchley, A | 1 |
| Rigopoulou, EI | 1 |
| Gyftaki, S | 1 |
| Arvaniti, P | 1 |
| Tsimourtou, V | 1 |
| Koukoulis, GK | 1 |
| Hadjigeorgiou, G | 1 |
| Dalekos, GN | 1 |
| Strijbos, E | 1 |
| Coenradie, S | 1 |
| Touw, DJ | 1 |
| Aerden, L | 1 |
| Rodriguez-Lojo, R | 1 |
| Castiñeiras, I | 1 |
| Juarez, Y | 1 |
| Lueiro, M | 1 |
| Armesto, A | 1 |
| Fernandez-Diaz, ML | 1 |
| Akaishi, T | 1 |
| Nakashima, I | 3 |
| Misu, T | 2 |
| Fujihara, K | 2 |
| Aoki, M | 1 |
| Acebal-Montero, A | 1 |
| Santos-Bueso, E | 1 |
| Fernández-Vigo, JI | 1 |
| Ávalos-Franco, N | 1 |
| Porta-Etessam, J | 1 |
| García-Sánchez, J | 1 |
| Hedayatfar, A | 1 |
| Falavarjani, KG | 1 |
| Soheilian, M | 1 |
| Elmi Sadr, N | 1 |
| Modarres, M | 1 |
| Parvaresh, MM | 1 |
| Naseripour, M | 1 |
| Rohani, M | 1 |
| Almasi, M | 1 |
| Chee, SP | 1 |
| Mameli, G | 1 |
| Cocco, E | 1 |
| Frau, J | 1 |
| Arru, G | 1 |
| Caggiu, E | 1 |
| Marrosu, MG | 1 |
| Sechi, LA | 1 |
| Takahashi, T | 1 |
| Itoyama, Y | 2 |
| Simó, M | 1 |
| Omata, K | 1 |
| Suzuki, N | 1 |
| Izumi, R | 1 |
| Nagata, M | 1 |
| Nishiyama, S | 1 |
| Sanvito, L | 1 |
| Tomita, A | 1 |
| Chihara, N | 1 |
| Okamoto, T | 2 |
| Lin, Y | 1 |
| Ogawa, M | 1 |
| Gran, B | 1 |
| Aranami, T | 1 |
| Yamamura, T | 2 |
| Turner, SJ | 1 |
| Dharmasena, A | 1 |
| Deane, J | 1 |
| Uzawa, A | 1 |
| Mori, M | 1 |
| Takahashi, Y | 1 |
| Ogawa, Y | 1 |
| Uchiyama, T | 1 |
| Kuwabara, S | 1 |
| Rampello, L | 2 |
| Malaguarnera, M | 1 |
| Nicoletti, G | 1 |
| Battaglia, G | 1 |
| Borhani-Haghighi, A | 1 |
| Ghodsi, M | 1 |
| Razeghinejad, MR | 1 |
| Mardani, S | 1 |
| Mardani, M | 1 |
| Nikseresht, AR | 1 |
| Safari, A | 1 |
| Bagheri, MH | 1 |
| Ikeda, K | 1 |
| Ohsawa, I | 1 |
| Furutera, R | 1 |
| Murata, M | 1 |
| Itoh, K | 1 |
| Umehara, F | 1 |
| Osame, M | 1 |
| Lieb, K | 1 |
| Engels, S | 1 |
| Fiebich, BL | 1 |
| Störh, M | 1 |
| Narayana, KM | 1 |
| Agrawal, R | 1 |
| Biswas, J | 1 |
| Arjundas, D | 1 |
| Schmidt, J | 1 |
| Metselaar, JM | 1 |
| Wauben, MH | 1 |
| Toyka, KV | 1 |
| Storm, G | 1 |
| Gold, R | 1 |
| LAUX, W | 2 |
| MILLER, H | 1 |
| NEWELL, DJ | 1 |
| RIDLEY, A | 1 |
| Tanosaki, M | 1 |
| Matsunaga, M | 1 |
| Morrow, SA | 1 |
| Stoian, CA | 1 |
| Dmitrovic, J | 1 |
| Chan, SC | 1 |
| Metz, LM | 1 |
| Mendhekar, DN | 1 |
| Mehta, R | 1 |
| Puri, V | 1 |
| Torkildsen, O | 1 |
| Vedeler, CA | 1 |
| Nyland, HI | 1 |
| Myhr, KM | 1 |
| Dovio, A | 1 |
| Perazzolo, L | 1 |
| Saba, L | 1 |
| Termine, A | 1 |
| Capobianco, M | 1 |
| Bertolotto, A | 1 |
| Angeli, A | 1 |
| Kumasaka, R | 1 |
| Nakamura, N | 1 |
| Shirato, K | 1 |
| Fujita, T | 1 |
| Murakami, R | 1 |
| Shimada, M | 1 |
| Nakamura, M | 1 |
| Osawa, H | 1 |
| Yamabe, H | 1 |
| Okumura, K | 1 |
| Schott, E | 1 |
| Paul, F | 1 |
| Wuerfel, JT | 1 |
| Zipp, F | 2 |
| Rudolph, B | 1 |
| Wiedenmann, B | 1 |
| Baumgart, DC | 1 |
| Yonekawa, T | 1 |
| Takahashi, J | 1 |
| Higuchi, K | 1 |
| Ihara, T | 1 |
| Gentile, S | 1 |
| Ferrero, M | 1 |
| Vaula, G | 1 |
| Rainero, I | 1 |
| Pinessi, L | 1 |
| Gomez-Gallego, M | 1 |
| Meca-Lallana, J | 1 |
| Fernandez-Barreiro, A | 1 |
| Ciccone, A | 1 |
| Beretta, S | 1 |
| Brusaferri, F | 1 |
| Galea, I | 1 |
| Protti, A | 1 |
| Spreafico, C | 1 |
| Schmidt, E | 1 |
| Mertin, J | 3 |
| Knight, SC | 2 |
| Rudge, P | 2 |
| Thompson, EJ | 2 |
| Healy, MJ | 1 |
| Kremer, M | 1 |
| Healey, MJ | 1 |
| Compston, A | 1 |
| Batchelor, JR | 1 |
| Halliday, AM | 1 |
| Denman, M | 1 |
| Medawar, PB | 1 |
| Hallpike, JF | 1 |
| Umanskiĭ, KG | 1 |
| Shishov, AS | 1 |
| Dekonenko, EP | 1 |
| Ashmarina, EE | 1 |
| Andreeva, LS | 1 |
| Golovkin, VI | 2 |
| Ankhimova, ES | 1 |
| Morozov, VG | 1 |
| Khavinson, VG | 1 |
| Harrer, G | 1 |
| Ishihara, O | 1 |
| Yamaguchi, Y | 1 |
| Matsuishi, T | 1 |
| Yano, E | 1 |
| Nakamura, Y | 1 |
| Tateishi, J | 1 |
| Yamashita, F | 1 |
| Veĭn, AM | 1 |
| Khomak, VIa | 1 |
| Belokrinitskiĭ, DV | 1 |
| Shkrob, OS | 1 |
| Golubkov, VA | 1 |
| Kogan, OG | 1 |
| Kanchurin, AKh | 1 |
| Kuznetsova, OV | 1 |
| Brusina, LI | 1 |
| Mel'nichuk, PV | 1 |
| Rogovina, NI | 1 |
| Khokhlov, AP | 1 |
| Wray, SH | 1 |
| Beck, RW | 3 |
| Kommerell, G | 1 |
| Wenning, GK | 1 |
| Wiethölter, H | 1 |
| Schnauder, G | 1 |
| Müller, PH | 1 |
| Kanduth, S | 1 |
| Renn, W | 1 |
| Slavin, ML | 1 |
| Burde, RM | 1 |
| Ohtsuka, T | 1 |
| Saito, Y | 1 |
| Hasegawa, M | 1 |
| Tatsuno, M | 1 |
| Takita, S | 1 |
| Arita, M | 1 |
| Okuyama, K | 1 |
| Trobe, JD | 2 |
| Tremlett, H | 1 |
| Martin, R | 1 |
| Lichtenfels, R | 1 |
| Roth, W | 1 |
| Dichgans, J | 1 |
| Krammer, PH | 1 |
| Weller, M | 1 |
| Federlein, J | 1 |
| Postert, T | 1 |
| Allgeier, A | 1 |
| Hoffmann, V | 1 |
| Pöhlau, D | 1 |
| Przuntek, H | 1 |
| Nagasawa, H | 1 |
| Takashima, S | 1 |
| Hirade, S | 1 |
| Inoue, H | 1 |
| Ossege, LM | 1 |
| Sindern, E | 1 |
| Voss, B | 1 |
| Malin, JP | 1 |
| Katz, B | 1 |
| Clear, D | 1 |
| Horiuchi, I | 1 |
| Mitsuo, K | 1 |
| Saida, K | 1 |
| Zhigang, Z | 1 |
| Ozawa, K | 1 |
| Konishi, T | 1 |
| Saida, T | 1 |
| Michałowska-Wender, G | 1 |
| Sudo, A | 1 |
| Endo, M | 1 |
| Saitoh, S | 1 |
| Abe, M | 1 |
| Tsuchiya, K | 1 |
| Kurosa, Y | 1 |
| Nakai, O | 1 |
| Shinomiya, K | 1 |
| Arndt, C | 1 |
| Sari, A | 1 |
| Ferre, M | 1 |
| Parrat, E | 1 |
| Courtas, D | 1 |
| De Seze , J | 1 |
| Hache, J | 1 |
| Matran, R | 1 |
| Ochi, H | 1 |
| Kira, J | 1 |
| Coombs, JM | 1 |
| Durcan, FJ | 1 |
| Tokuda, T | 1 |
| Oide, T | 1 |
| Tamaoka, A | 1 |
| Ishii, K | 1 |
| Matsuno, S | 1 |
| Ikeda, S | 1 |
| Biggins, JA | 1 |
| Caspary, EA | 1 |
| Raptis, S | 1 |
| von Berger, L | 1 |
| Dollinger, HC | 1 |
| Fazekas, AA | 1 |
| Pfeiffer, EF | 1 |
| Gekht, BM | 2 |
| Kuzin, MI | 1 |
| Kolomenskaia, EA | 2 |
| Gnezditskaia, EV | 1 |
| Zefirova, GS | 1 |
| Takatsu, M | 1 |
| Toyokura, Y | 1 |
| Matsumoto, N | 1 |
| Miwa, S | 1 |
| Agte, BS | 1 |
| Zemlianaia, NF | 1 |
| Kalmykova, TN | 1 |
| Dukhovnaia, MA | 1 |
| Leonovich, AL | 1 |
| Gitkina, LS | 1 |
| McDonald, E | 1 |
| Miró, J | 1 |
| Aguayo, F | 1 |
| Garrido, JC | 1 |
| Alvarez, C | 1 |
| Polo, JM | 1 |
| Pascual, J | 1 |
| Berciano, J | 1 |
| Iarosh, AA | 4 |
| Tiazhkorob, AM | 1 |
| Prokopiv, MM | 2 |
| Kanevskaia, SA | 2 |
| Zhovnir, IK | 2 |
| Neretin, VIa | 4 |
| Lobov, MA | 1 |
| Kotov, SV | 1 |
| Safronova, OG | 1 |
| Ruutiainen, J | 1 |
| Salonen, R | 1 |
| Halonen, P | 1 |
| Panelius, M | 1 |
| Eskola, J | 1 |
| Salmi, A | 1 |
| Odinokova, VA | 1 |
| Kir'iakov, VA | 3 |
| Sapfirova, VA | 3 |
| Chernigovskaia, NV | 1 |
| Ogurtsov, RP | 1 |
| Matveeva, TS | 1 |
| Popov, VG | 1 |
| Puzyreva, VP | 1 |
| Schmitt, E | 1 |
| Behm, E | 1 |
| Buddenhagen, F | 2 |
| Ernst, B | 1 |
| Hitzschke, B | 2 |
| Kracht, M | 1 |
| Korten, G | 1 |
| Kundt, G | 1 |
| Meyer-Rienecker, H | 1 |
| Osten, B | 1 |
| Macheret, EL | 1 |
| Zapadniuk, BV | 1 |
| Brainin, M | 1 |
| Neuhold, A | 1 |
| Reisner, T | 1 |
| Maida, E | 1 |
| Lang, S | 1 |
| Deecke, L | 1 |
| Dachsel, R | 1 |
| Köppel, C | 1 |
| Rodeck, U | 1 |
| Kuwert, E | 1 |
| Scharafinski, HW | 1 |
| Lehmann, HJ | 1 |
| Shagal, DI | 1 |
| Merkulova, DM | 1 |
| Ibragimova, GV | 1 |
| Meyer-Rienecker, HJ | 1 |
| Richter, M | 1 |
| Gannushkina, IV | 1 |
| Zhirnova, IG | 1 |
| Lyons, PR | 1 |
| Newman, PK | 1 |
| Saunders, M | 1 |
| Ochudło, S | 1 |
| Lobzin, VS | 2 |
| Bagdasarova, IA | 1 |
| Ohno, R | 1 |
| Hamaguchi, K | 1 |
| Sowa, K | 1 |
| Tanaka, H | 1 |
| Watanabe, Y | 1 |
| Bardasarova, IA | 1 |
| Inoue, YK | 1 |
| Nishibe, Y | 1 |
| Melnick, JL | 1 |
| Seidel, E | 1 |
| Wang, SS | 1 |
| Ring, J | 1 |
| Seifert, J | 2 |
| Lob, G | 1 |
| Coulin, K | 1 |
| Angstwurm, H | 2 |
| Frick, E | 2 |
| Brass, B | 1 |
| Backmund, H | 1 |
| Brendel, W | 2 |
| Strauss, G | 1 |
| Baumann, J | 1 |
| Poppe, W | 1 |
| Schwenkbier, H | 1 |
| Wieczorek, V | 2 |
| Minderhoud, JM | 1 |
| Fazio, C | 1 |
| Agnoli, A | 1 |
| Cecconi, V | 1 |
| Casacchia, M | 1 |
| Schock, G | 1 |
| Göpel, W | 2 |
| Benkenstein, H | 1 |
| Banzhaf, M | 1 |
| Witmer, R | 1 |
| Shimizu, T | 1 |
| Bertram, W | 1 |
| Land, W | 1 |
| Hopf, U | 1 |
| Rabassini, A | 1 |
| Bernardi, S | 1 |
| Bammer, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Tolerability of Acthar for the Treatment of Multiple Sclerosis Relapses (TAMS)[NCT02258217] | 30 participants (Actual) | Interventional | 2014-06-30 | Completed | |||
| [NCT00000147] | 0 participants | Interventional | 1988-07-31 | Active, not recruiting | |||
| [NCT00000146] | Phase 3 | 0 participants | Interventional | 1988-07-31 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Patients completed the ARMS survey after treatment for the new relapse.The ARMS questionnaire (assessing relapses in multiple sclerosis) was developed by a panel of expert MS nurses. Part one consists of 7 questions designed to assess relapse symptoms, impact on activities of daily living, and response to past treatment for MS relapses. Part two consists of 7 questions to evaluate treatment response in terms of relief from symptoms, functioning and tolerability.~The TCS score was calculated only for the time point after treatment of relapse. It was a sum of questions 4 (symptom improvement), 5 (ADL), and 6 (return to previous state of health (RSH)) were evaluated. Scores range from 0 to 30 units, with higher scores representing greater improvement/better functioning." (NCT02258217)
Timeframe: Follow-up visit
| Intervention | score on a scale (Mean) |
|---|---|
| Single Arm | 14.3 |
"Patient history of prior corticosteroid tolerability for the treatment of MS relapses. This will be determined based on patient completion of the ARMS survey at the baseline visit. Also, history of patients from the survey after treatment for the new relapse will be collected.~The ARMS questionnaire (assessing relapses in multiple sclerosis) was developed by a panel of expert MS nurses. Part one consists of 7 questions designed to assess relapse symptoms, impact on activities of daily living, and response to past treatment for MS relapses. Part two consists of 7 questions to evaluate treatment response in terms of relief from symptoms, functioning and tolerability.~ADL scores were calculated from Part 1 (new relapse), question 3 and Part 2 (after treatment of relapse), question 5 both specifically refer to ADL;~Scale: ADL (Activities of Daily Living) Minimum value: 0 Maximum value: 9 Higher scores indicated better functioning/ improvement." (NCT02258217)
Timeframe: baseline visit & follow-up after treatment
| Intervention | score on a scale (Mean) | |
|---|---|---|
| ADL (new relapse) | ADL (after treatment of relapse) | |
| Single Arm | 3.1 | 4.9 |
"Patient history of prior corticosteroid tolerability for the treatment of MS relapses. This will be determined based on patient completion of the ARMS survey at the baseline visit. Also, patients completed the survey after treatment for the new relapse.~The ARMS questionnaire (assessing relapses in multiple sclerosis) was developed by a panel of expert MS nurses. Part one consists of 7 questions designed to assess relapse symptoms, impact on activities of daily living, and response to past treatment for MS relapses. Part two consists of 7 questions to evaluate treatment response in terms of relief from symptoms, functioning and tolerability.~PCS was computed based on the sum of the ADL and RSH questions. The PCS was computed separately for Part 1 (new relapse) and Part 2 (after relapse treatment) and summarized descriptively; Higher scores indicating better functioning/greater improvement. The PCS scores were on a scale of 0 to 20 units." (NCT02258217)
Timeframe: baseline visit & follow-up after treatment
| Intervention | score on a scale (Mean) | |
|---|---|---|
| PCS (New relapse) | PCS (after treatment of relapse) | |
| Single Arm | 7.7 | 9.2 |
"Patient history of prior corticosteroid tolerability for the treatment of MS relapses. This will be determined based on patient completion of the ARMS survey at the baseline visit. Also, patients completed the survey after treatment for the new relapse. The ARMS questionnaire (assessing relapses in multiple sclerosis) was developed by a panel of expert MS nurses. Part one consists of 7 questions designed to assess relapse symptoms, impact on activities of daily living, and response to past treatment for MS relapses. Part two consists of 7 questions to evaluate treatment response in terms of relief from symptoms, functioning and tolerability.~Part 1 (new relapse) & Part 2 (after treatment of new relapse), question 6 were used to calculate RSH;~Scale: RSH (Return to previous health) Minimum value: -1 Maximum value: 10 Higher scores indicating a more complete return to previous state of health." (NCT02258217)
Timeframe: baseline visit & follow-up after treatment
| Intervention | score on a scale (Mean) | |
|---|---|---|
| RSH (new relapse) | RSH (after treatment of new relapse) | |
| Single Arm | 4.6 | 4.4 |
"This scaling score is obtained by performing a neurologic exam with specific attention to eight different neurologic functional systems: visual, pyramidal, cerebellar, bowel and bladder, cerebral, brainstem, sensory and other (10). The score is rated from zero (normal neurologic examination) to ten (death due to MS). This is the standard neurologic disability scale used in clinical trials for the evaluation of disability in patients with MS.~These scores were compared between pre and post phase using paired t-tests." (NCT02258217)
Timeframe: baseline and at follow-up
| Intervention | score on a scale (Median) | |
|---|---|---|
| EDSS score (new relapse) | EDSS score (after treatment of new relapse) | |
| Single Arm | 3.5 | 3.0 |
"Patients who reported a history of poor corticosteroid tolerability will be placed on Acthar and GASE scale will be given to assess tolerability to Acthar.~We listed the number of times a symptom was reported and was attributable to the ACTHAR treatment" (NCT02258217)
Timeframe: 1 week
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Headache | Dry Mouth | Dizziness | Tachycardia, palpitation or arrhythmia | Breathing problems | Abdominal pain | Nausea | Diarrhea | Reduced Appetite | Increased appetite | Difficulties with urination | Skin rash or itching | Tendency to develop bruises | Sweating | Hot flashes | Fatigue, loss of energy | Insomnia, sleeping problems | Nightmares or abnormal dreams | Back pain | Agitation | Irritability | Depressed Mood | Anxiety, fearfulness | Further symptoms | |
| Single Arm | 3 | 1 | 2 | 1 | 1 | 4 | 4 | 4 | 1 | 4 | 2 | 1 | 1 | 1 | 1 | 2 | 8 | 2 | 1 | 6 | 6 | 3 | 1 | 8 |
"The MSIS-29 is a self-reported questionnaire in which MS patients answer a series of 29 questions designed to capture the impact of multiple sclerosis on their life over the past 2 weeks (11). Twenty of the 29 questions assess the physical impact of MS and 9 questions assess the psychological impact of MS.~The psychological impact of MS was compared between pre and post phase using paired t-tests.~The psychological impact of MS was compared between pre and post phase using paired t-tests.~The score was on a scale of 9 to 45 points for MSIS psychological score.~Higher score indicate worse outcome." (NCT02258217)
Timeframe: baseline visit & follow-up after treatment
| Intervention | score on a scale (Mean) | |
|---|---|---|
| MSIS psychological(new relapse) | MSIS psychological(after treatment of new relapse) | |
| Single Arm | 29.4 | 26.3 |
"The MSIS-29 is a self-reported questionnaire in which MS patients answer a series of 29 questions designed to capture the impact of multiple sclerosis on their life over the past 2 weeks (11). Twenty of the 29 questions assess the physical impact of MS.~The physical impact of MS was compared between pre and post phase using paired t-tests. Each question is answered with points ranging from 1 to 5. Higher score indicates worse outcome. The total MSIS physical score ranges from 20 to 100 points with lower points indicating better impact." (NCT02258217)
Timeframe: baseline visit & follow-up after treatment
| Intervention | score on a scale (Median) | |
|---|---|---|
| MSIS physical (new relapse) | MSIS physical (after treatment of new relapse) | |
| Single Arm | 58.5 | 56 |
"The Self-Administered Gerocognitive Exam (SAGE) is designed to detect early signs of cognitive, memory or thinking impairments. It evaluates your thinking abilities and helps physicians to know how well your brain is working.~It consists of 12 questions which are scored at different scales. The final SAGE score is calculated as a sum of these 12 questions and it ranges from 0 to 22.~Higher score indicates better outcome." (NCT02258217)
Timeframe: baseline and follow-up
| Intervention | score on a scale (Median) | |
|---|---|---|
| SAGE (new relapse) | SAGE (after treatment of new relapse) | |
| Single Arm | 21 | 21 |
15 reviews available for prednisolone and MS (Multiple Sclerosis)
| Article | Year |
|---|---|
[Neuromyelitis optica and anti-aquaporin 4 antibody--distinct from multiple sclerosis].
Topics: Aquaporin 4; Astrocytes; Autoantibodies; Autoimmunity; Azathioprine; Biomarkers; Humans; Immunoglobu | 2009 |
[Therapy of multiple sclerosis].
Topics: Adjuvants, Immunologic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Diagnosis, Differ | 2009 |
[Multiple sclerosis].
Topics: Autoimmunity; Combined Modality Therapy; Humans; Immunosuppressive Agents; Interferon-beta; Leukaphe | 2004 |
FcgammaR and multiple sclerosis: an overview.
Topics: Animals; Anti-Inflammatory Agents; Encephalomyelitis, Autoimmune, Experimental; Humans; Mice; Multip | 2006 |
Corticosteroids for the long-term treatment in multiple sclerosis.
Topics: Adrenal Cortex Hormones; Disease Progression; Humans; Long-Term Care; Methylprednisolone; Multiple S | 2008 |
New treatments for multiple sclerosis.
Topics: Adrenocorticotropic Hormone; Antilymphocyte Serum; Azathioprine; Desensitization, Immunologic; Dieta | 1980 |
Optic neuritis: guidelines.
Topics: Clinical Protocols; Disease Progression; Humans; Methylprednisolone; Multiple Sclerosis; Optic Neuri | 1995 |
The optic neuritis treatment trial: implications for clinicians.
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Clinical Trials as Topic; Female; Humans; Male; Methylp | 1995 |
[Multiple sclerosis].
Topics: Animals; Autoimmunity; Diagnosis, Differential; Glatiramer Acetate; Humans; Immunoglobulins, Intrave | 2000 |
[Steroid therapy for neurologic diseases--indications and methods of administration].
Topics: Adrenocorticotropic Hormone; Cortisone; Facial Paralysis; Female; Humans; Middle Aged; Multiple Scle | 1979 |
[Steroid therapy for hematologic diseases--indications and methods of administration].
Topics: Adrenal Cortex Hormones; Agranulocytosis; Anemia, Aplastic; Anemia, Hemolytic, Autoimmune; Hematolog | 1979 |
Multiple sclerosis: common management issues.
Topics: Brain; Combined Modality Therapy; Humans; Immunosuppression Therapy; Magnetic Resonance Imaging; Met | 1992 |
[Immunosuppressive therapy of various autoimmune diseases of the nervous system].
Topics: Autoimmune Diseases; Azathioprine; Cyclophosphamide; Drug Evaluation; Humans; Multiple Sclerosis; My | 1990 |
[Immunosuppressive treatment of multiple sclerosis (review of the literature].
Topics: Adrenocorticotropic Hormone; Antilymphocyte Serum; Autoimmune Diseases; Azathioprine; Combined Modal | 1990 |
[Multiple sclerosis].
Topics: Adrenocorticotropic Hormone; Diseases in Twins; Female; Humans; Immunoglobulins; Multiple Sclerosis; | 1974 |
14 trials available for prednisolone and MS (Multiple Sclerosis)
| Article | Year |
|---|---|
Erythropoietin for acute multiple sclerosis in patients with optic neuritis as a first demyelination event.
Topics: Acute Disease; Adolescent; Adult; Demyelinating Diseases; Drug Therapy, Combination; Erythropoietin; | 2012 |
The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents; Area Under Curve; Biological Availability; Bi | 2004 |
Double-blind, controlled trial of immunosuppression in treatment of multiple sclerosis.
Topics: Antilymphocyte Serum; Azathioprine; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Com | 1980 |
Double-blind controlled trial of immunosuppression in the treatment of multiple sclerosis: final report.
Topics: Adolescent; Adult; Antilymphocyte Serum; Azathioprine; Clinical Trials as Topic; Double-Blind Method | 1982 |
The optic neuritis treatment trial: three-year follow-up results.
Topics: Drug Therapy, Combination; Follow-Up Studies; Humans; Methylprednisolone; Multiple Sclerosis; Optic | 1995 |
The optic neuritis treatment trial: three-year follow-up results.
Topics: Drug Therapy, Combination; Follow-Up Studies; Humans; Methylprednisolone; Multiple Sclerosis; Optic | 1995 |
The optic neuritis treatment trial: three-year follow-up results.
Topics: Drug Therapy, Combination; Follow-Up Studies; Humans; Methylprednisolone; Multiple Sclerosis; Optic | 1995 |
The optic neuritis treatment trial: three-year follow-up results.
Topics: Drug Therapy, Combination; Follow-Up Studies; Humans; Methylprednisolone; Multiple Sclerosis; Optic | 1995 |
[Treatment of optic neuritis with corticosteroids. Discussion at the 10th Meeting of the International Neuro-ophthalmological Society (Freiburg 5 to 9 June 1994)].
Topics: Administration, Oral; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, | 1994 |
What we have learned from the Optic Neuritis Treatment Trial.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Anti-Inflammatory Agents; Brain; Female; Hum | 1995 |
What we have learned from the Optic Neuritis Treatment Trial.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Anti-Inflammatory Agents; Brain; Female; Hum | 1995 |
What we have learned from the Optic Neuritis Treatment Trial.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Anti-Inflammatory Agents; Brain; Female; Hum | 1995 |
What we have learned from the Optic Neuritis Treatment Trial.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Anti-Inflammatory Agents; Brain; Female; Hum | 1995 |
Long-term open-trial of mizoribine with prednisolone in 24 patients with multiple sclerosis: safety, clinical and magnetic resonance imaging outcome.
Topics: Adolescent; Adult; Algorithms; Anti-Inflammatory Agents; Child; Drug Therapy, Combination; Female; H | 1999 |
Prednisolone (30-60 mg/day) for diseases other than AD decreases amyloid beta-peptides in CSF.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Amyloid beta-Peptides; Brain; Cranial Nerve Di | 2002 |
Treatment of acute exacerbations in early multiple sclerosis: cyclosporin A or prednisolone?
Topics: Acute Disease; Adult; Cyclosporins; Double-Blind Method; Humans; Multiple Sclerosis; Neurologic Exam | 1991 |
Immunoadsorption (IA) versus plasma exchange (PE) in multiple sclerosis--first results of a double blind controlled trial.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Humans; Immunosorbent Techniques; Multiple Sc | 1990 |
[Corticosteroid therapy of multiple sclerosis with attention to biorhythms].
Topics: Adrenal Cortex Diseases; Adrenal Cortex Hormones; Adult; Clinical Trials as Topic; Female; Humans; M | 1986 |
[Corticosteroid therapy of disseminated sclerosis].
Topics: Administration, Oral; Adult; Clinical Trials as Topic; Drug Administration Schedule; Female; Humans; | 1985 |
Intensive immunosuppression in the treatment of multiple sclerosis.
Topics: Adult; Animals; Antilymphocyte Serum; Azathioprine; Cells, Cultured; Drainage; Drug Therapy, Combina | 1974 |
89 other studies available for prednisolone and MS (Multiple Sclerosis)
| Article | Year |
|---|---|
Refractory chronic spontaneous urticaria after the use of alemtuzumab in multiple sclerosis.
Topics: Adult; Alemtuzumab; Anti-Allergic Agents; Cetirizine; Chronic Urticaria; Female; Glucocorticoids; Hu | 2020 |
Modulation of Th17 Proliferation and IL-17A Gene Expression by Acetylated Form of Apigenin in Patients with Multiple Sclerosis.
Topics: Acetylation; Adult; Anti-Inflammatory Agents; Apigenin; Cell Proliferation; Cells, Cultured; Female; | 2021 |
Can pulse steroid therapy increase the risk of infection by COVID-19 in patients with multiple sclerosis?
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; COVID-19; Cross-Sectional Studies; Female; | 2021 |
Immune thrombocytopenic purpura associated with fingolimod.
Topics: Blood Platelets; Disease Management; Female; Fingolimod Hydrochloride; Glucocorticoids; Humans; Immu | 2017 |
A case of severe drug reaction secondary to alemtuzumab with successful re-exposure.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal, Humanized; Blister; Clinical Trials, Phase III as Topic; | 2017 |
Development of acquired haemophilia A in a patient treated with alemtuzumab for multiple sclerosis.
Topics: Adult; Alemtuzumab; Antineoplastic Agents, Immunological; Diagnosis, Differential; Factor VIIa; Fact | 2018 |
Autoimmune hepatitis in patients with multiple sclerosis: The role of immunomodulatory treatment.
Topics: Adult; Autoantibodies; Azathioprine; Female; Glucocorticoids; Hepatitis, Autoimmune; Humans; Immunol | 2019 |
High-dose methylprednisolone for multiple sclerosis during lactation: Concentrations in breast milk.
Topics: Female; Humans; Immunologic Factors; Milk, Human; Multiple Sclerosis; Prednisolone; Pregnancy; Pregn | 2015 |
Sweet syndrome associated with interferon.
Topics: Adjuvants, Immunologic; Adult; Female; Glucocorticoids; Humans; Interferon beta-1b; Leg; Multiple Sc | 2014 |
Depressive state and chronic fatigue in multiple sclerosis and neuromyelitis optica.
Topics: Adult; Aged; Carnitine; Chronic Disease; Comorbidity; Depression; Fatigue; Female; Gait Disorders, N | 2015 |
Atypical presentation of multiple sclerosis.
Topics: Brain Neoplasms; Diagnosis, Differential; Female; Glioma; Hemianopsia; Humans; Immunosuppressive Age | 2016 |
Mycophenolate Mofetil for the Treatment of Multiple Sclerosis-associated Uveitis.
Topics: Adolescent; Adult; Chemotherapy, Adjuvant; Enzyme Inhibitors; Female; Fluorescein Angiography; Gluco | 2017 |
Serum BAFF levels, Methypredsinolone therapy, Epstein-Barr Virus and Mycobacterium avium subsp. paratuberculosis infection in Multiple Sclerosis patients.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antibodies, Bacterial; B-Cell Activating Factor; Epitopes; Ep | 2016 |
[Case of multiple sclerosis with "yes-yes" type head tremor].
Topics: Adult; Anticonvulsants; Cervical Vertebrae; Clonazepam; Female; Head; Humans; Magnetic Resonance Ima | 2011 |
Increase of Ki-67+ natural killer cells in multiple sclerosis patients treated with interferon-β and interferon-β combined with low-dose oral steroids.
Topics: Administration, Oral; Cells, Cultured; Cohort Studies; Cross-Sectional Studies; Drug Therapy, Combin | 2011 |
Bilateral rubeosis iridis and rubeotic glaucoma due to peripheral occlusive vasculitis associated with multiple sclerosis.
Topics: Acetazolamide; Adult; Glaucoma, Neovascular; Humans; Immunosuppressive Agents; Iritis; Light Coagula | 2011 |
Anti-N-methyl D-aspartate-type glutamate receptor antibody-positive limbic encephalitis in a patient with multiple sclerosis.
Topics: Adult; Anti-Inflammatory Agents; Autoantibodies; Brain; Cognition Disorders; Female; Humans; Limbic | 2012 |
Stabbing headache in patients with autoimmune disorders.
Topics: Adolescent; Adult; Age of Onset; Aged; Anti-Inflammatory Agents; Autoimmune Diseases; Demyelinating | 2012 |
[Nephrotic syndrome in multiple sclerosis patients who had undergone long-term interferon β-1b therapy].
Topics: Adult; Female; Glomerulonephritis, Membranous; Humans; Interferon beta-1b; Interferon-beta; Kidney; | 2013 |
Multifocal relapsing-remitting myelitis in a patient with atopic dermatitis: multiple sclerosis or atopic myelitis?
Topics: Adult; Dermatitis, Atopic; Diagnosis, Differential; Female; Humans; Immunoglobulin E; Magnetic Reson | 2002 |
Inhibition of LPS-induced iNOS and NO synthesis in primary rat microglial cells.
Topics: Algorithms; Animals; Anti-Inflammatory Agents; Blotting, Western; Cells, Cultured; Enzyme Induction; | 2003 |
[Comments on the contribution, "Immunomodulating staged therapy of multiple sclerosis by the Multiple Sclerosis Therapy Consensus Group"].
Topics: Consensus Development Conferences as Topic; Dose-Response Relationship, Drug; Drug Administration Sc | 2002 |
Recurrent anterior uveitis and healed retinal vasculitis associated with multiple sclerosis.
Topics: Female; Glucocorticoids; Humans; Magnetic Resonance Imaging; Middle Aged; Multiple Sclerosis; Predni | 2003 |
Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis.
Topics: Animals; Apoptosis; Brain; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Fema | 2003 |
[On treating multiple sclerosis with hydrocortisone].
Topics: Humans; Hydrocortisone; Multiple Sclerosis; Prednisolone; Psychotherapy, Multiple | 1956 |
[On treating multiple sclerosis with hydrocortisone].
Topics: Humans; Hydrocortisone; Multiple Sclerosis; Prednisolone; Psychotherapy, Multiple | 1956 |
[On treating multiple sclerosis with hydrocortisone].
Topics: Humans; Hydrocortisone; Multiple Sclerosis; Prednisolone; Psychotherapy, Multiple | 1956 |
[On treating multiple sclerosis with hydrocortisone].
Topics: Humans; Hydrocortisone; Multiple Sclerosis; Prednisolone; Psychotherapy, Multiple | 1956 |
Multiple sclerosis. Trials of maintenance treatment with prednisolone and soluble aspirin.
Topics: Aspirin; Humans; Multiple Sclerosis; Prednisolone | 1961 |
Successful steroid therapy in multiple sclerosis presented as acute psychosis.
Topics: Acute Disease; Adult; Female; Glucocorticoids; Humans; Multiple Sclerosis; Prednisolone; Psychotic D | 2004 |
High-dose glucocorticoids increase serum levels of soluble IL-6 receptor alpha and its ratio to soluble gp130: an additional mechanism for early increased bone resorption.
Topics: Adult; Biomarkers; Bone Resorption; Calcium; Cytokine Receptor gp130; Female; Glucocorticoids; Human | 2006 |
Nephrotic syndrome associated with interferon-beta-1b therapy for multiple sclerosis.
Topics: Adjuvants, Immunologic; Adult; Biopsy; Female; Glucocorticoids; Humans; Interferon beta-1b; Interfer | 2006 |
Development of ulcerative colitis in a patient with multiple sclerosis following treatment with interferon beta 1a.
Topics: Adjuvants, Immunologic; Adult; Colitis, Ulcerative; Female; Glatiramer Acetate; Humans; Immunity, In | 2007 |
[Hypogeusia in a 9-year-old girl with multiple sclerosis].
Topics: Ageusia; Brain; Child; Drug Administration Schedule; Female; Humans; Magnetic Resonance Imaging; Mul | 2007 |
Cluster headache attacks and multiple sclerosis.
Topics: Adult; Anti-Inflammatory Agents; Cluster Headache; Diagnosis, Differential; Functional Laterality; H | 2007 |
Multiple sclerosis onset during etanercept treatment.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Etanercept; Female; Glucocorti | 2008 |
[Experiences with intrathecal corticosteroid treatment of polysclerosis and other neurological diseases].
Topics: Adolescent; Adult; Female; Humans; Injections, Spinal; Male; Meningoencephalitis; Middle Aged; Multi | 1967 |
[Immunotherapy of certain acute and chronic forms of neuroinfections (tick-borne encephalitis, multiple sclerosis, disseminated encephalomyelitis)].
Topics: Adult; Antibodies, Viral; Encephalitis, Tick-Borne; Encephalomyelitis; Female; Humans; Interferons; | 1981 |
[Use of a thymus polypeptide preparation to diagnose and correct immune deficiency states in multiple sclerosis].
Topics: Adjuvants, Immunologic; Adult; Humans; Immunologic Deficiency Syndromes; Leukocyte Count; Middle Age | 1984 |
[Therapeutic measures in multiple sclerosis].
Topics: Adrenocorticotropic Hormone; Azathioprine; Cyclophosphamide; Fatty Acids, Nonesterified; Humans; Mul | 1980 |
Multiple ring enhancement in a case of acute reversible demyelinating disease in childhood suggestive of acute multiple sclerosis.
Topics: Cerebrospinal Fluid; Child, Preschool; Diagnosis, Differential; Humans; Male; Multiple Sclerosis; Pr | 1984 |
[Thymectomy in disseminated sclerosis].
Topics: Adolescent; Adult; Autoimmune Diseases; B-Lymphocytes; Chronic Disease; Humans; Middle Aged; Multipl | 1981 |
[Glial migration inhibition test in multiple sclerosis patients and its changes during treatment with immunosuppressants].
Topics: Antilymphocyte Serum; Cell Migration Inhibition; Cyclophosphamide; Diagnosis, Differential; Humans; | 1981 |
[Changes of clinico-biochemical indicators in multiple sclerosis treated with hormones and antioxidants].
Topics: Adult; Female; Histidine; Humans; Lipid Peroxides; Male; Malonates; Malondialdehyde; Middle Aged; Mu | 1980 |
Recovery of the hypothalamic-pituitary-adrenal axis from suppression by short-term, high-dose intravenous prednisolone therapy in patients with MS.
Topics: Adrenocorticotropic Hormone; Adult; Dose-Response Relationship, Drug; Female; Humans; Hydrocortisone | 1994 |
Prepublication blackout in the Optic Neuritis Treatment Trial.
Topics: Clinical Trials as Topic; Humans; Multiple Sclerosis; Optic Neuritis; Prednisolone; Publishing; Time | 1994 |
Central nervous system disease in a child with primary Sjögren syndrome.
Topics: Brain; Child; Diagnosis, Differential; Encephalomyelitis; Female; Hemiplegia; Humans; Immunoglobulin | 1995 |
Oral versus intravenous corticosteroids in acute relapses of multiple sclerosis.
Topics: Administration, Oral; Glucocorticoids; Humans; Infusions, Intravenous; Methylprednisolone; Multiple | 1997 |
Human autoreactive and foreign antigen-specific T cells resist apoptosis induced by soluble recombinant CD95 ligand.
Topics: Antibodies, Monoclonal; Apoptosis; Autoimmune Diseases; Autoimmunity; bcl-2-Associated X Protein; bc | 1997 |
Remitting parkinsonism as a symptom of multiple sclerosis and the associated magnetic resonance imaging findings.
Topics: Anti-Inflammatory Agents; Humans; Magnetic Resonance Imaging; Male; Mesencephalon; Middle Aged; Mult | 1997 |
[A case of multiple sclerosis with relapses during the third trimester of pregnancy].
Topics: Adult; Anti-Inflammatory Agents; Cesarean Section; Female; Humans; Magnetic Resonance Imaging; Methy | 1997 |
Corticosteroids induce expression of transforming-growth-factor-beta1 mRNA in peripheral blood mononuclear cells of patients with multiple sclerosis.
Topics: Adult; Anti-Inflammatory Agents; Female; Humans; Leukocytes, Mononuclear; Male; Multiple Sclerosis; | 1998 |
Anaphylactoid reaction to methyl prednisolone developing after starting treatment with interferon beta-1b.
Topics: Adult; Anaphylaxis; Humans; Interferon beta-1a; Interferon beta-1b; Interferon-beta; Male; Multiple | 1999 |
[A case of multiple sclerosis with abnormal single photon emission computed tomography (SPECT)].
Topics: Adult; Anti-Inflammatory Agents; Ataxia; Cerebellum; Female; Humans; Multiple Sclerosis; Prednisolon | 1999 |
The early stage of multiple sclerosis in the light of molecular and immunological studies.
Topics: Adult; Anti-Inflammatory Agents; Autoantibodies; Biomarkers; Gene Rearrangement, T-Lymphocyte; Human | 1999 |
[Serum anti-arrestin antibody and disease activity of multiple sclerosis--a case report of 4-year-old child].
Topics: Arrestin; Autoantibodies; Biomarkers; Child, Preschool; Female; Humans; Methylprednisolone; Multiple | 2000 |
Multiple sclerosis with very late onset: a report of a case with onset at age 82 years and review of the literature.
Topics: Age of Onset; Aged; Aged, 80 and over; Humans; Magnetic Resonance Imaging; Male; Multiple Sclerosis; | 2000 |
Electrophysiological effects of corticosteroids on the retinal pigment epithelium.
Topics: Animals; Cattle; Cells, Cultured; Choroid; Electrooculography; Electrophysiology; Glucocorticoids; G | 2001 |
Postoperative inflammation in a patient with multiple sclerosis.
Topics: Acute Disease; Female; Glucocorticoids; Humans; Lens Implantation, Intraocular; Middle Aged; Multipl | 2001 |
Letter: Effect of prednisolone on lymphocyte transformation in multiple sclerosis.
Topics: Adult; Aged; Female; Humans; Lectins; Lymphocyte Activation; Male; Middle Aged; Mitogens; Multiple S | 1975 |
Hypergastrinemia induced by glucocorticoid and corticotropin treatment in man.
Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Arthritis, Rheumatoid; Gastrins; Glucocorticoids; Hu | 1976 |
[Pathogenetic therapy of nervous system and muscular diseases using large doses of prednisolone on alternate days].
Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Corticosterone; Humans; Hydrocortisone; Methods; Mid | 1979 |
[Immunosuppressive agents in complex treatment of disseminated sclerosis].
Topics: Adult; Azathioprine; Cyclophosphamide; Female; Humans; Immunosuppressive Agents; Male; Mercaptopurin | 1976 |
[Use of glucocorticoid hormones in multiple sclerosis].
Topics: Acute Disease; Adolescent; Adult; Chronic Disease; Female; Glucocorticoids; Humans; Male; Multiple S | 1976 |
Intrathecal immunoglobulin synthesis in multiple sclerosis: effect of corticosteroids and azathioprine.
Topics: Administration, Oral; Adrenocorticotropic Hormone; Adult; Azathioprine; Drug Administration Schedule | 1992 |
[Changes in the clinical and immunological indices of patients with disseminated sclerosis being treated with prednisolone].
Topics: Antigen-Antibody Complex; Central Nervous System Diseases; Chronic Disease; Combined Modality Therap | 1991 |
[Treatment of prednisolone-dependent form of multiple sclerosis].
Topics: Adult; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Humans; Hyperbaric Oxyge | 1991 |
[Clinico-immunologic parallels in evaluating the treatment of multiple sclerosis].
Topics: Acute Disease; Adolescent; Adult; B-Lymphocytes; Dexamethasone; Drug Therapy, Combination; Etimizol; | 1990 |
[The effect of prednisolone on the immunoglobulin content of the blood in patients with disseminated sclerosis].
Topics: Adult; Antibody Formation; Combined Modality Therapy; Humans; Immunoglobulins; Multiple Sclerosis; P | 1990 |
[Changes in the immunological reactivity of patients with disseminated sclerosis treated by prednisolone and the preparation Proper-Myl].
Topics: Adult; B-Lymphocytes; Biological Products; Combined Modality Therapy; Drug Combinations; Drug Therap | 1990 |
Changes within the "normal" cerebral white matter of multiple sclerosis patients during acute attacks and during high-dose cortisone therapy assessed by means of quantitative MRI.
Topics: Acute Disease; Adolescent; Adult; Aged; Brain; Female; Humans; Magnetic Resonance Imaging; Male; Mid | 1989 |
[Initial experiences with the Reiber 1979 determination of autochthonous IgG production within the scope of clinical and immunologic follow-up studies in multiple sclerosis treated with immunosuppressive therapy].
Topics: Azathioprine; Cyclophosphamide; Disability Evaluation; Drug Therapy, Combination; Follow-Up Studies; | 1989 |
T lymphocyte populations in multiple sclerosis.
Topics: Adult; Antigens, Surface; Female; Humans; Leukocyte Count; Male; Middle Aged; Multiple Sclerosis; Pr | 1985 |
[Strategy for using glucocorticoid preparations in neuromuscular diseases].
Topics: Autoimmune Diseases; Humans; Multiple Sclerosis; Muscular Diseases; Myositis; Nerve Compression Synd | 1985 |
[The problem and value of therapy in multiple sclerosis].
Topics: Adult; Antilymphocyte Serum; Azathioprine; Cyclophosphamide; Female; Follow-Up Studies; Humans; Male | 1988 |
[The dynamics of immunological indicators in the treatment of patients with multiple sclerosis with prednisolone combined with plasmapheresis].
Topics: Adult; B-Lymphocytes; Combined Modality Therapy; Female; Humans; Immunoglobulins; Leukocyte Count; L | 1988 |
Methylprednisolone therapy in multiple sclerosis: a profile of adverse effects.
Topics: Administration, Oral; Adolescent; Adult; Dose-Response Relationship, Drug; Humans; Infusions, Intrav | 1988 |
[Effect of the treatment with encorton (Polfa) on the production of immunoglobulin G in the central nervous system of patients with multiple sclerosis].
Topics: Brain; Humans; Immunoglobulin G; Multiple Sclerosis; Prednisolone | 1987 |
High-dose intravenous corticosteroids in the treatment of multiple sclerosis.
Topics: Administration, Oral; Adolescent; Adrenal Cortex Hormones; Adult; Disability Evaluation; Humans; Inj | 1987 |
Inhibitory effect of glucocorticoid hormones on the growth of Inoue-Melnick virus.
Topics: Cell Line; Cytopathogenic Effect, Viral; Dose-Response Relationship, Drug; Humans; Hydrocortisone; M | 1985 |
[Immunsuppressive treatment of multiple sclerosis. 2. Critical review of general results (author's transl)].
Topics: Antilymphocyte Serum; Azathioprine; Chronic Disease; Cyclophosphamide; Drug Therapy, Combination; Fo | 1974 |
Results of treatment of certain diseases of the central nervous system with ACTH and corticosteroids.
Topics: Adrenocorticotropic Hormone; Adult; Amyotrophic Lateral Sclerosis; Brain Diseases; Dystonia Musculor | 1965 |
[50th contribution of the Central Expert Committee for Drug Trade, Section Human Medicine].
Topics: Adrenocorticotropic Hormone; Antilymphocyte Serum; Azathioprine; Cyclophosphamide; Humans; Multiple | 1973 |
Study in multiple sclerosis with a plurichronocorticoid respecting the circadian rhythms.
Topics: Adrenocorticotropic Hormone; Circadian Rhythm; Cortisone; Drug Combinations; Drug Evaluation; Humans | 1974 |
[Meningitis after intrathecal administration of corticosteroids].
Topics: Adult; Humans; Injections, Spinal; Male; Meningitis; Middle Aged; Multiple Sclerosis; Prednisolone | 1974 |
[Immunosuppressive therapy of multiple sclerosis using cyclophosphamide and imuran. Report on 57 cases].
Topics: Acute Disease; Adolescent; Adult; Azathioprine; Chronic Disease; Cyclophosphamide; Female; Humans; M | 1972 |
[Neuritis optica].
Topics: Adolescent; Adult; Aged; Arteritis; Child; Dexamethasone; Diagnosis, Differential; Female; Fluoresce | 1972 |
[Clinical studies of neuro-Behcet's syndrome--with special reference to epidemiological and clinicopathological studies].
Topics: Adolescent; Adult; Arthritis, Rheumatoid; Behcet Syndrome; Brain; Child; Demyelinating Diseases; Fem | 1972 |
[Experiences with intrathecal glucocorticoid therapy in inflammatory neurological diseases (35 case reports)].
Topics: Adult; Aged; Arachnoiditis; Child; Chronic Disease; Encephalitis; Encephalomyelitis; Female; Hernia; | 1971 |
[Attempt for an induction of immune tolerance against horse IgG in men].
Topics: Adult; Antibodies; Antibody Formation; Antigens; Antilymphocyte Serum; Azathioprine; Female; Hemaggl | 1970 |
[Multifocal therapy of multiple sclerosis, with special reference to lysozyme therapy].
Topics: Humans; Multiple Sclerosis; Muramidase; Prednisolone; Saccharomyces | 1966 |
[Ceruloplasmin and copper metabolism in multiple sclerosis].
Topics: Cerebrospinal Fluid Proteins; Ceruloplasmin; Copper; Hepatolenticular Degeneration; Humans; Methods; | 1966 |